The Microcyn Technology platform is used to manufacture tissue care products which reduce the need for antibiotics while reducing infections and accelerating healing.
The Microcyn Technology features a biocompatible, shelf-stable solution that is currently commercialized in the US, Europe, India, China and Mexico and select Middle East countries under various country specific regulatory clearances and approvals.
AmDerma Pharmaceuticals will pay Oculus $500,000 as a non-refundable initial payment as an option to license the Microcyn technology for an acne new drug application.
Quinnova Pharmaceuticals has licensed the US and Canadian rights to the recently-cleared Microcyn-based dermatology atopic dermatitis hydrogel for a $500,000 prepayment and ongoing double-digit royalties.
Amneal will co-promote the current Rx Microcyn-based wound care products to podiatry professionals in the US and Canada.
Oculus CEO Hoji Alimi said the breadth of Amneal Enterprises’ alliance members’ resources will help advance the extraordinary promise of Microcyn.
Members of Amneal Enterprises include Amneal Pharmaceuticals, Prolong Pharmaceuticals, AmDerma Pharmaceuticals, Quinnova Pharmaceuticals, Kashiv Pharma and TcNet.